The Next Phase of Patient Finance

Chapter Seven

From fragmented growth to system-level pressure

1. The market has grown — but not stabilised

Over the past decade:

• dental patient finance has grown:

  • from ~£60–70m

  • to £600m+ annually

Driven by:

• Invisalign and cosmetic dentistry

• increased private treatment volumes

• gradual adoption across practices

But this growth has happened:

without a corresponding evolution in system design

Reality

• processes remain fragmented

• underwriting remains inconsistent

• integration remains limited

Growth has masked structural weakness

2. The broker model has already declined

As of 2026:

• traditional brokers:

  • largely diminished at scale

• control has shifted toward:

  • lenders

  • or platforms with funding access

Remaining question

What replaces the broker role fully?

• pure lenders lack integration

• platforms require scale and capital

3. Repeated market entry — and exit

Over the past decade, multiple players have attempted to enter:

Examples

• Klarna

• Affirm (exploration)

• humm (Australia)

• HSBC (Divido)

• Barclays

• BNP Paribas

• Close Brothers (partial exit)

Common outcome

• entry

• limited traction

• exit or retrenchment

Why?

• fragmented provider base

• high variability in practice performance

• lack of standardisation

• difficulty underwriting at scale

Key insight

Dentistry looks simple from the outside—but behaves like a highly segmented risk market.

4. Scale is not enough

Large lenders have:

• cheap capital

• experience in retail finance

Yet, they have not dominated dentistry

Reason

The constraint is not capital—it is system integration and underwriting context

• patient-level behaviour matters

• treatment-level outcomes matter

• practice-level variation matters

5. Regulation is resetting the market

From 2026:

• all loans become regulated

• full Section 75 exposure applies

• full FCA oversight required

Immediate implications

• higher compliance burden

• increased operational cost

• greater exposure to claims

Structural implication

The margin for error is reduced

Previously: risk could be partially avoided

Now: risk must be actively managed

6. Risk is being redistributed

Large lenders are already responding:

• insuring parts of portfolios

• focusing on larger counterparties

Emerging question

Who serves the long tail?

• independent practices

• small groups

• variable performance profiles

7. Growth vs risk tension

The market now faces a fundamental trade-off:

To grow:

• expand access

• approve more patients

• serve more practices

To manage risk:

• tighten underwriting

• restrict counterparties

• limit exposure

Structural tension

The strategies required for growth and risk control are no longer aligned

8. Market behaviour is still price-led

Despite:

• evidence on conversion

• operational cost differences

• system advantages

Decision-making remains:

• negotiation-driven

• price-focused

Key question

Will practices shift from price optimisation to outcome optimisation?

9. The role of technology is expanding

New capabilities now exist:

• AI-driven communication

• integrated PMS workflows

• automated follow-ups

But adoption is uneven

• some practices:

  • fully embrace systemisation

• others:

  • remain manual

Emerging divide

Between system-led practices and process-led practices

10. What remains unresolved

As of 2026, several key questions remain open:

1. Who will serve SME (independents and small groups)?

• lenders prefer scale and ability to sell/insure Section 75 risk

• Section 75 risk increases will also apply to previously unregulated activity

2. Can underwriting improve fast enough?

• more data needed

• more integration required

3. Will regulation trigger consolidation?

• increased cost base

• higher compliance burden

4. Will practices change behaviour?

• From: price

• To: conversion and system performance

5. What is the sustainable market size?

• £1bn+ likely

• but dependent on:

  • adoption

  • system efficiency

  • risk management

Final reflection

The first phase of patient finance was about making it available. The second phase is about making it work—at scale, under regulation, and with real risk.

What remains unclear is not whether the market will grow. But who will be able to operate within it sustainably.